20258-97-3Relevant academic research and scientific papers
Selective irreversible inhibition of fructose 1,6-bisphosphate aldolase from Trypanosoma brucei
Dax, Chantal,Duffieux, Francis,Chabot, Nicolas,Coincon, Mathieu,Sygusch, Jurgen,Michels, Paul A. M.,Blonski, Casimir
, p. 1499 - 1502 (2006)
An irreversible competitive inhibitor hydroxynaphthaldehyde phosphate was synthesized that is highly selective against the glycolytic enzyme fructose 1,6-bisphosphate aldolase from Trypanosoma brucei (causative agent of sleeping sickness). Inhibition invo
SMALL MOLECULE INHIBITORS OF A PROTEIN COMPLEX
-
Paragraph 00164, (2020/12/29)
Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.
Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease
Lu, Chuan-Jun,Hu, Jinhui,Wang, Zechen,Xie, Shishun,Pan, Tingting,Huang, Ling,Li, Xingshu
, p. 1862 - 1870 (2018/11/24)
A novel series of boron-containing compounds were designed, synthesized and evaluated as multi-target-directed ligands against Alzheimer's disease. The biological activity results demonstrated that these compounds possessed a significant ability to inhibit self-induced Aβ aggregation (20.5-82.8%, 20 μM) and to act as potential antioxidants (oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values of 2.70-5.87). In particular, compound 17h is a potential lead compound for AD therapy (IC50 = 3.41 μM for self-induced Aβ aggregation; ORAC-FL value = 4.55). Compound 17h also functions as a metal chelator. These results indicated that boron-containing compounds could be new structural scaffolds for the treatment of AD.
Benzo-hexatomic ring derivative used as DPP-4 inhibitor and application of benzo-hexatomic ring derivative
-
Paragraph 0184; 0185; 0186; 0187, (2016/10/09)
The invention relates to a benzo-hexatomic ring derivative used as a DPP-4 inhibitor and application of the benzo-hexatomic ring derivative, in particular to compounds shown as in formula I, medicine compositions with the compounds shown as in the formula I and application of the compounds in preparing medicines for treating diseases related to DPP-4 or inhibiting the DPP-4.
